["3-(4","5-Dimethylthiazol-2-yl)-2","5-diphenyltetrazolium bromide"]

414.32

413.030975

3825277

206-069-5

EUY85H477I

60102|367079

Yellow powder

29341000

75.7

log Kow = -2.32 /Estimated/

Yellow to orange powder

1.4886 (estimate)

195 °C (dec.)(lit.)

H2O: Slightly soluble ;methanol: 5 mg/mL, clear

2-8°C

5.11X10-11 mm Hg at 25 deg C /Estimated/

Henry's Law constant= 5.4X10-22 atm-cu m/mole at 25 °C /Estimated/

Hydroxyl radical reaction rate constant= 1.7X10-11 cu cm/molecule-sec at 25 °C /Estimated/

NONH for all modes of transport

3

46-68-36/37/38

22-24/25-53-45-36/37-26

XF8060000

Xi,T,Xn

P261-P281-P305 + P351 + P338

H315-H319-H335-H341

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

KB cells were treated with MTT at final concentrations up to 0.2 mg/ml alone or in combination with methotrexate (10 and 32 uM). When used alone, as little as 0.025 mg/ml increased population doubling time from 26 hr (control) to 96 hr. At 0.2 mg/ml or higher, total cell number declined. MTT, 0.1 mg/ml, reduced the number of cells in S and G2/M phases after 8 hr treatment. However, no significant effect was seen at 2 and 4 hr. The effect of 0.2 mg/ml MTT was more immediate and more pronounced, resulting in accumulation of cells in G0/G1 and S phases. MTT in combination with methotrexate produced a more significant perturbation in the KB cell cycle.|...Phenazine methosulfate (PMS) and MTT are often used in combination: however, PMS did not potentiate the mutagenicity of MTT.

Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide

2H-Tetrazolium, 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-, bromide (1:1): ACTIVE|The MTT assay is simple, accurate and yields reproducible results. This method has been developed originally by Mossman in 1983. The key component is (3-[4,5-dimethylthiazol-2-yl]- 2,5-diphenyl tetrazolium bromide) or MTT. Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, leading to the formation of purple crystals which are insoluble in aqueous solutions. The crystals are re-dissolved in acidified isopropanol and the resulting purple solution is measured spectrophotometrically. An increase or decrease in cell number results in a concomitant change in the amount of formazan formed, indicating the degree of cytotoxicity caused by the test material (IC50).|A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation. The assay detects living, but not dead cells and the signal generated is dependent on the degree of activation of the cells. This method can therefore be used to measure cytotoxicity, proliferation or activation. The results can be read on a multiwell scanning spectrophotometer (ELISA reader) and show a high degree of precision.|/The authors/ compared the MTT assay to the standard clonogenic assay and had good agreement of surviving fraction /of murine solid tumor cells/ after radiation doses of 2 and 4 Gy. It is possible, therefore, to adapt the MTT assay for use with cell suspensions prepared directly from fresh murine tumors. This may provide a methodology for the determination of the clinical radiosensitivity of tumors including fresh clinical tumor specimens.|A microcytotoxicity assay employing a tetrazolium salt has been adapted for testing the response of human leukemic blast cells to a variety of chemotherapeutic agents. After exposure to various concentrations of drugs, the viability of fresh leukemic blast cells was measured using a tetrazolium salt, MTT, which is converted to blue formazan crystals by living cells. The amount of formazan produced was quantitated using a microtiter plate spectrophotometer.